Biogen Idec Says Long-Lasting Hemophilia Drug Meets Safety Goals

Biogen Idec (BIIB) and Swedish Orphan Biovitrum said a potential hemophilia B treatment has metsafety goals in an early-stage study.

The study involved 14 previously treated patients, and the data showed that the drug, rFIXFc, was well tolerated and demonstrated an approximately three-fold increase in half-life, compared to previous data for existing therapies. That would give provide prolonged protection with a single dose.

The study was presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010. Based on this study, the companies said they'll conduct a global registrational trial of the safety and effectiveness of the drug with 75 patients.

Hemophilia is a rare, inherited disorder in which patients have an impaired ability for blood clotting, leading to excessive bleeding. Current treatments require intravenous injections twice a week. This drug, the companies hope, would reduce the injections to once a week.

Read Full Story

Markets

DJIA 26,743.50 86.52 0.32%
NASDAQ 7,986.96 -41.28 -0.51%
NIKKEI 225 23,869.93 195.00 0.82%
HANG SENG 27,493.10 -460.48 -1.65%
DAX 12,389.20 -41.68 -0.34%
USD (per EUR) 1.17 0.00 -0.05%
USD (per CHF) 0.96 0.00 0.17%
JPY (per USD) 112.59 0.07 0.06%
GBP (per USD) 1.31 0.00 0.23%